E. Acosta: Dose-Response Curves and Inhibitory Potential of ARV
Dr. Edward Acosta, Pharm MD Associate professor University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA. The long-term goals of Dr. Acosta's laboratory is to optimize antiviral dosing strategies in adult and pediatric patients through integration of pharmacokinetic, pharmacodynamic, virologic, and pharmacogenetic data
He was appointed to the faculty in 1999 after serving as an Assistant Professor at the University of Minnesota and was promoted to Associate Professor in 2004. He is Director of the UAB Antiviral Pharmacology Laboratory, which focuses on antiviral assay development and pharmacometrics. Dr. Acosta is the Principal Investigator of the UAB Adult and IMPAACT Pharmacology Laboratories, and network pharmacologist for the Collaborative Antiviral Study Group funded through the National Institutes of Health. Dr. Acosta's laboratory has developed HPLC-UV, LC/MS, and LC/MS/MS assays to quantitate most of the currently available antiviral and antiretroviral drugs in plasma and other matrices. The laboratory has the expertise to conduct noncompartmental pharmacokinetic analyses and apply complex state-of-the-art individual and population pharmacokinetic and pharmacodynamic models to concentration-time and concentration-response data. The UAB Antiviral Pharmacology Laboratory has published over 100 manuscripts and presented findings at major national and international conferences. The long-term goals of the laboratory are to optimize antiviral dosing strategies in adult and pediatric patients through integration of pharmacokinetic, pharmacodynamic, virologic, and pharmacogenetic data.